The European Network for Acute Coronary Treatment (ENACT) study was designed to collect prospective information across Europe on the relative frequency, diagnosis and management of the whole spectrum of acute coronary syndromes.
Aim
The European Network for Acute Coronary Treatment (ENACT) study was designed to collect prospective information across Europe on the relative frequency, diagnosis and management of the whole spectrum of acute coronary syndromes.
Methods Cardiologists, who were respondents to mailings sent out to 17 European countries with the target of reaching one centre per million inhabitants, completed a prospective patient record, each physician providing information on 10 consecutive patients with a working diagnosis on admission of acute coronary syndrome, and a questionnaire.
Results A total of 390 responses were received (0·91/10 6 population) with data on 3092 patients in 29 countries. The patient population comprised 1431 (46%) with an initial working diagnosis of unstable angina/non-ST-segment elevation myocardial infarction, 1205 (39%) with myocardial infarction and 445 (14%) with suspected acute coronary syndrome. The ratio of unstable angina to myocardial infarction was 1·2:1 and this was similar across Europe. An initial diagnosis of myocardial infarction was more likely to be confirmed than unstable angina or suspected acute coronary syndrome. There were wide variations in the rates of angiography and percutaneous coronary intervention across Europe. Most unstable angina patients received aspirin, nitrates and heparin (unfractionated heparin 44% intravenous, 16% subcutaneous; low-molecular-weight heparin 50%). Overall, 50% of unstable angina patients and 34% of myocardial infarction patients received lowmolecular-weight heparin and 6% and 8% respectively received a glycoprotein IIb/IIIa inhibitor, but there were large inter-country differences. There were also national differences in the use of calcium antagonists, angiotensinconverting enzyme inhibitors and beta-blockers.
Introduction
The acute coronary syndromes -myocardial infarction, non-Q-wave myocardial infarction and unstable angina -are common causes of emergency hospital admission and a major burden on health care resources in industrialized countries.
The diagnostic criteria and major treatment strategies, including reperfusion therapy, for ST-segment elevation myocardial infarction are well defined [1] . However, acute coronary syndromes without ST-segment elevation (unstable angina and non-Q wave myocardial infarction) are more heterogeneous and have greater variation in diagnostic criteria and treatment. Valuable information is gained from clinical trials, but such patients represent a selected minority and an uncertain proportion of the total number with the syndrome. The prevalence of recognized unstable angina appears to be increasing and data from North America suggest that it is now more common than acute myocardial infarction [2] . Whether this is a reflection of the success of interventions such as patient education and the management of coronary risk factors in reducing the incidence of myocardial infarction, or altered thresholds for presentation and diagnosis of unstable angina, remains uncertain. Demographic changes, including the ageing of the population, may also play a part. Interventional strategies in unstable angina/non-Q wave myocardial infarction and the positive findings of recent pharmacological trials including those with lowmolecular-weight heparins and glycoprotein IIb/IIIa inhibitors, have also led to greater attention being focused on this condition. However, despite this growing interest, there is a paucity of pan-European information on the diagnosis and treatment of acute coronary syndromes.
Epidemiological surveys provide a useful means of identifying variations in clinical practice and their effect on outcomes. For example, national surveys have been undertaken of the early management of acute myocardial infarction in Sweden [3] , Germany [4] and France [5, 6] , and of coronary artery bypass graft surgery in the U.K. [7] . However, few surveys have been undertaken on a pan-European basis and none has addressed the acute management of the whole spectrum of acute coronary syndromes. The European Action on Secondary Prevention through Intervention to Reduce Events (EUROA-SPIRE) survey [8] focused on secondary prevention. Whilst the Organisation to Assess Strategies for Ischaemic Syndromes (OASIS) study [9] did examine unstable angina specifically, it did not provide representative data for Europe, since Poland and Hungary were the only European countries participating, and only centres participating in a clinical trial were included. Hence, there is an urgent need for information about the management and outcome of acute coronary syndromes in Europe.
To meet this need, the ENACT (European Network for Acute Coronary Treatment) study was designed to collect information about the whole spectrum of acute coronary syndromes and, importantly, to establish the proportion of unstable angina relative to that of myocardial infarction.
Methods
The distribution of cardiologists across Europe was established from national and international sources and a series of mailings were sent to cardiologists in 17 European countries. This consisted of a first announcement and up to two reminders for non-responders. All those who expressed interest in participating were sent the study documents, comprising the patient record, data sheet and questionnaire. Participants were asked to complete the patient record with information on consecutive patients admitted to their unit with symptoms of unstable angina or acute myocardial infarction during a 7-day period between April and June 1999. Large units were asked to collect data on the first 10 patients admitted during the survey period. Participants were asked to specify the working diagnosis on admission in one of three categories according to their usual criteria: myocardial infarction, unstable angina/non-ST elevation myocardial infarction, suspected acute coronary syndrome. A positive response to both unstable angina/non-ST elevation myocardial infarction and myocardial infarction was coded as suspected acute coronary syndrome.
The patient record was used to collect data on patient characteristics (demographic data, prior medical history, ECG abnormalities and biochemical markers), final/ discharge diagnosis, medical treatment during the index admission, invasive procedures, duration of coronary or intensive care unit (CCU/ICU) stay and total hospital stay. Each participating physician was also asked to complete a short questionnaire regarding the hospital facilities, the criteria used to diagnose unstable angina, and the management of three hypothetical case studies. Presented here are the major findings of the study from the analysis of the patient record forms. The results of the questionnaire will be published separately. Details of the study design have been published [10] . Although only 17 European countries were targeted, responses were received from centres in 29 countries.
Results

Response rates
More than 1000 physicians expressed an interest in participating in ENACT and 390 centres in 29 countries The ENACT study 1441 participated in the study. There were 360 responses from 17 targeted countries, equivalent to 0·91/10 6 population in these countries (this excluded Eastern European countries, Israel, Egypt and Cyprus, countries that were not targeted and from which only a few responses were received). The 390 completed patient records included data on 3092 patients.* In total, there were 1638 patients in community hospitals, 1095 in university/teaching hospitals and 343 in university-affiliated hospitals (data were not available for 16 patients).
Working diagnosis at admission
There were 1431 patients (46%) with unstable angina/ non-ST elevation myocardial infarction, 1205 (39%) with myocardial infarction and 445 (14%) with suspected acute coronary syndrome. The ratio of unstable angina to myocardial infarction was 1·2:1 overall and was similar in all European countries (Fig. 1) . The proportions of patients with a diagnosis of unstable angina was higher in university hospitals (51%) than in community hospitals (43%), reflecting a lower proportion of patients in whom there was initial diagnostic uncertainty or greater confidence by the physician in his/her diagnosis (17% in community hospitals and 11% in university hospitals with suspected acute coronary syndrome).
Demographics
The clinical and demographic characteristics are summarized in Table 1 . The mean ages were similar across all countries and, overall, 30% of patients were female.
The frequency of cardiac risk factors other than smoking was higher in unstable angina patients than in myocardial infarction patients, while there were more smokers among the myocardial infarction patients. More patients with unstable angina had a history of cardiovascular disease and more had undergone prior revascularization.
Time from onset of symptoms
The majority of patients (65%) presented within 12 h of the onset of pain ( Table 2 ). The proportion presenting within 12 h was highest in Scandinavia (79%) and in Belgium/The Netherlands (77%) and lowest in Eastern Europe (51%). More patients with unstable angina presented late (23%>24 h, 13%>72 h) compared with myocardial infarction patients (13%>24 h, 5%>72 h).
ECG abnormalities
Information was collected on the worst ECG recorded in the first 24 h after admission. Among the entire patient population, there were 1331 patients with STsegment elevation (>1 mm) in at least two leads, 1432 with other ECG changes and 329 with a normal ECG *ENACT patient population: Switzerland/Austria (n=65); Belgium/The Netherlands (n=133); Scandinavia (n=182); France (n=254); Germany (n=304); Greece (n=276); Italy (n=463); Spain (n=364); Turkey (n=116); U.K./Ireland (n=639); Eastern Europe (n=221). Data from reference [10] . ( Fig. 2) . ST-segment elevation was strongly associated with an initial diagnosis of acute myocardial infarction. Myocardial infarction was the initial diagnosis in 77% of those with this abnormality; conversely, ST elevation was present in 85% of those with an initial diagnosis of myocardial infarction. The initial diagnosis was unstable angina in 17% of patients with ST elevation and suspected acute coronary syndrome in 6%. Among patients with other ECG abnormalities, the initial diagnosis was acute myocardial infarction in 12%, unstable angina in 70% and suspected acute coronary syndrome in 18%. In the smaller group of 329 patients with normal ECGs, the initial diagnosis was acute myocardial infarction in 4%, unstable angina in 63% and suspected acute coronary syndrome in 31%.
The final diagnosis was myocardial infarction in most patients with ST elevation (76%) (Fig. 3) . The presence of other ECG abnormalities usually preceded a final diagnosis of unstable angina (58%); however, in a quarter of these patients the final diagnosis was myocardial infarction and in a further 8% myocardial infarction evolved from unstable angina. Only 6% of patients with ECG abnormalities were eventually diagnosed with a non-cardiac condition. In contrast, 23% of those with a normal ECG had a non-cardiac diagnosis, but in 10% the final diagnosis was myocardial infarction.
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Biochemical markers
Troponin measurements were available for 36% of all patients. Among unstable angina patients in whom they were available, 62% were in the normal range, 12% were less than twice the upper limit of normal, 13% were 2-5 times normal and 14% were >5 times normal. The corresponding figures for myocardial infarction patients were 20%, 11%, 14% and 55%. Peak creatine kinase-MB was >2 times normal in 66% of patients with a final diagnosis of myocardial infarction compared with 4% of those with a final diagnosis of unstable angina and 41% of those with a final diagnosis of myocardial infarction evolved from unstable angina. There were wide differences in the availability of troponin data: it was highest in Switzerland/Austria and Germany and lowest in Belgium/The Netherlands and Greece.
Final diagnosis and mortality rate
The working diagnosis on admission was relatively accurately predictive of the final diagnosis, especially for myocardial infarction (Fig. 4) . In 93% of cases, an initial diagnosis of acute myocardial infarction was subsequently confirmed, and the proportion in whom the eventual diagnosis was non-cardiac was extremely low (1%). In contrast, the final diagnosis was acute myocardial infarction in 20% and non-cardiac in 25% of those with an initial diagnosis of suspected acute coronary syndrome. Heart failure was reported in 23% of myocardial infarction patients compared with 16% of unstable angina patients.
The in-hospital mortality rates according to the admission diagnosis were 1·6% in unstable angina, 6·0% in myocardial infarction and 2·0% in suspected acute coronary syndrome. The figures were similar by final diagnosis: 0·7% in unstable angina, 4·3% in myocardial infarction evolved from unstable angina and 5·9% in myocardial infarction. Mortality was 1·0% in those with a non-cardiac final diagnosis. These data exclude patients dying before hospitalization or dying in transit to the unit.
Reperfusion therapy for myocardial infarction
A high proportion of myocardial infarction patients received thrombolytic therapy: 51% by initial diagnosis and 43% by final diagnosis, while 8% and 7% respectively were treated with primary percutaneous coronary intervention. However, there were wide variations between countries (Fig. 5 university teaching (11%) and university-affiliated (17%) hospitals than in community hospitals (4%).
Pharmacological treatment
With regard to other medical treatment, most myocardial infarction patients received aspirin (96%), nitrates (80%) and some form of heparin (90%) and there was relatively little variation among countries (Table 3) . There was wide variation in the use of calcium antagonists, beta-blockers, low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors. The countries with the highest use of beta-blockers (Scandinavia, 84%, and Belgium/The Netherlands, 82%) had the lowest use of angiotensin-converting enzyme (ACE) inhibitors (37% and 45% respectively). Overall use of low-molecularweight heparin was 34% in myocardial infarction; however, this varied between 11% in Italy and 64% in Greece. Eight per cent of myocardial infarction patients received a glycoprotein IIb/IIIa inhibitor, and the proportions ranged from none in Turkey to a third in Germany. The use of glycoprotein IIb/IIIa inhibitors was highest in the countries with the highest percutaneous coronary intervention rates. Most unstable angina patients also received aspirin, nitrates and some form of heparin (Table 4) ; as with myocardial infarction patients, there were more national variations in the use of other drugs. Half of all unstable angina patients received low-molecular-weight heparin, with the highest use in France, Austria/Switzerland, Greece and Scandinavia and the lowest use in Italy. A glycoprotein IIb/IIIa inhibitor was administered to 6% of all unstable angina patients; the proportion receiving an agent of this class was highest in Austria/Switzerland, Germany and Belgium/The Netherlands.
Angiography and percutaneous coronary intervention
Marked variation between countries was seen in the availability and use of cardiac catheterization in the management of acute coronary syndromes. Overall, 41% of unstable angina patients underwent coronary angiography during the index admission and the procedure was scheduled in a further 21%. However, the proportion undergoing angiography varied from 19% in the U.K./Ireland to 68% in France. Percutaneous coronary intervention was performed in 23% of unstable angina patients, ranging from 9% in Greece and the U.K./ Ireland to 49% in France. There were also major national differences in the use of angiography and percutaneous coronary intervention in myocardial infarction patients. Overall, 33% of myocardial infarction patients underwent angiography and 23% underwent percutaneous coronary intervention. LMW=low-molecular weight, GP=glycoprotein.
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The angiography rates ranged from 6% in Greece to 79% in Germany and the percutaneous coronary intervention rates ranged from 7% in Greece to 62% in Germany. Almost half (48%) of percutaneous coronary interventions in myocardial infarction patients were emergency procedures. As noted above, primary percutaneous coronary intervention was widely practised in France and Germany. More patients underwent invasive procedures in university hospitals (49% angiography, 31% percutaneous coronary intervention) than in community hospitals (24% angiography, 13% percutaneous coronary intervention).
Stents were placed during 68% of percutaneous coronary interventions, with relatively little variation between countries or types of hospital.
Length of hospital stay
The average length of stay for patients with an initial diagnosis of unstable angina was 8·5 days of which 3·4 days were spent in the CCU/ICU. The CCU/ICU stay varied between 2·9 days in Germany and almost 4 days (3·8 days in Greece and Belgium/The Netherlands, 3.9 days in Italy), and the total hospital stay varied between 7·3 days in the U.K./Ireland and 10·7 days in Belgium/ The Netherlands (Fig. 6) .
Myocardial infarction patients typically spent 9·6 days in hospital including 4·1 days in the CCU/ICU. The length of stay in the CCU/ICU ranged from 3·0 days in Belgium/The Netherlands to 4·9 days in France, while the total hospital stay varied between 7·9 days in the U.K./Ireland and 12·6 days in Eastern Europe (Fig. 7) . LMW=low-molecular weight, GP=glycoprotein. According to the final diagnosis, the total hospital stay was 8·3 days for unstable angina, 9·7 days for myocardial infarction, 9·8 days for myocardial infarction evolved from unstable angina and 6·3 days for noncardiac diagnoses.
Discussion
Until now, relatively more information has been available for myocardial infarction than for unstable angina, but this has been mainly on a national basis, with the exception of the EUROASPIRE data [8] , which were pan-European but confined to risk factors and secondary prevention. For unstable angina, most of the available information has come from clinical trials; these provide useful data, but the data are often derived from limited geographical areas and the patient populations are typically highly selected to meet trial criteria and hence unrepresentative of the whole patient population. The MONICA Project [11] has generated a large volume of data on 10-year trends in the incidence of acute coronary events and coronary heart disease case fatality; however, a restricted population was studied in each participating country, the diagnostic criteria for myocardial infarction were specific to the project and unstable angina was not characterized.
For the first time, the ENACT study has now given us comparative European data on the relative frequency of unstable angina and myocardial infarction as a cause of hospital admission. The ratio in Europe is 1·2:1, a figure identical to that reported from the U.S.A. [12] . The ratio is remarkably consistent across Europe; only Eastern Europe varied from this pattern and this variation may have been the consequence of the small numbers of returns from each individual Eastern European country. The apparent increase in unstable angina relative to myocardial infarction may be related to survivors of an episode of unstable angina or myocardial infarction presenting again.
The results of the ENACT study highlight the enormous impact of unstable angina on health care resources in Europe. It is at least as common as acute myocardial infarction as a cause of hospital admission in Europe and the initial treatment consumes as many resources. Unstable angina patients typically spent 8·5 days (3·4 days in the CCU/ICU) in hospital, little less than those with myocardial infarction, who stayed for a mean of 9·6 days (4·1 days in CCU/ICU). It could be argued that, with the availability of current techniques for diagnosis and risk stratification combined with newer treatments, it is unnecessary for the majority of patients to remain in hospital for so long. The study also highlights the fact that a diagnosis of unstable angina or suspected acute coronary syndrome is the trigger for costly investigations, with angiography undertaken or scheduled in 62% of unstable angina patients.
The demographic data show that the patient population in this study was very similar to other high-risk coronary heart disease populations. The prevalence of risk factors in myocardial infarction patients was very similar to that observed in myocardial infarction patients in EUROASPIRE [8] . The results show that the majority of patients (65% overall, 72% of myocardial infarction patients) present within 12 h of the onset of symptoms. However, in one-third, the delay is more than 12 h and 23% of unstable angina patients presented more than 24 h after the onset of symptoms. The myocardial infarction delays are in line with the Minnesota data, which showed that 40% of myocardial infarction patients presented more than 6 h after the onset of symptoms [13] and highlight that this is still an important issue to be addressed. This is the first time that information on delay in presentation has been published for a large series of unstable angina patients. It is well established that time to initiation of thrombolysis has a significant impact on the outcome of myocardial infarction [14] , and recently evidence has been presented to support the intuitive expectation that earlier treatment is better in unstable angina. It was shown in a retrospective analysis of data from the Platelet IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT) trial that earlier initiation of a glycoprotein IIb/IIIa inhibitor is associated with a greater reduction of coronary events [15] . Reperfusion therapy is regarded as standard therapy for most myocardial infarction patients with ST-segment elevation, and at present thrombolytic therapy and primary angioplasty are regarded as valid alternatives [1, 16, 17] . The results of ENACT indicate that 51% of patients with an admission diagnosis of acute myocardial infarction received thrombolytic therapy with a further 8% undergoing primary percutaneous coronary intervention. However, primary percutaneous coronary intervention was practised much more widely in France and Germany than in other European countries (with a correspondingly lower use of thrombolysis) and in the U.K./Ireland less than 1% of patients received this treatment. These findings are in line with national trends in the use of angiography and angioplasty reported elsewhere [18] . However, it appears that the use of primary angioplasty in France has increased since the 1995 registry reported by Danchin et al. [6] . Troponin measurements are now recognized as a valuable diagnostic tool [19] , but the data reported here indicate that the availability of troponin testing is still very limited in Europe. This is the first time that comparative data have been published on acute pharmacological treatment of myocardial infarction and unstable angina in Europe. The results show high use of aspirin, heparin and betablockers, in line with the clinical evidence [1, 20, 21] . The use of calcium antagonists is more controversial and we cannot draw any conclusions from this study about the appropriateness of their use. The high use of ACE inhibitors in unstable angina (44%) is somewhat surprising, given the lack of clinical trial evidence in this indication (prior to presentation of the HOPE results [22] ), and is likely to be related to co-morbidities
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(heart failure and hypertension). The use of ACE inhibitors in Eastern Europe (69% in unstable angina, 70% in myocardial infarction) is very high, but is in accord with EUROASPIRE, in which the highest use was observed in Hungary [8] . In many countries, low-molecular-weight heparin has been adopted quite widely in unstable angina, in line with the clinical evidence that it is at least equivalent or superior to unfractionated heparin [23] . More than 50% of patients in most countries received low-molecularweight heparin; Italy is a major exception. One-third of myocardial infarction patients also received lowmolecular-weight heparin.
The use of glycoprotein IIb/IIIa inhibitors was very low in both myocardial infarction (8%) and unstable angina (6%) and reflects use mainly in conjunction with percutaneous coronary intervention. At the time that ENACT was carried out, abciximab was the only glycoprotein IIb/IIIa inhibitor available in Europe and its licence restricts its use to patients undergoing percutaneous coronary intervention or scheduled for this procedure. Since the ENACT data were collected, two small-molecule glycoprotein IIb/IIIa inhibitors, tirofiban and eptifibatide, have been approved for use in unstable angina and non-Q wave myocardial infarction in Europe and it is likely that this will result in a considerable expansion in the use of this class.
We found a wide variation in the use of invasive procedures in Europe, with the use of percutaneous coronary intervention for both unstable angina and acute myocardial infarction highest in France and Germany. This is in line with the findings of the Working Group on Coronary Circulation of the European Society of Cardiology [18] and generally mirrors the observations in the PURSUIT study [24, 25] . The angiography and percutaneous coronary intervention rates were surprisingly high in Eastern Europe and may reflect a higher proportion of university hospitals participating in ENACT in this region (66% of patients compared with 35% in the whole population) and a bias towards English-speaking centres, as the documentation was in English.
The observed mortality rates in myocardial infarction were lower than expected and lower than reported elsewhere [26] ; however, this is not surprising since patients were only included in the study after admission to a hospital bed and hence deaths prior to that time were not documented. The reported mortality rate for patients with myocardial infarction evolved from unstable angina was almost as high as in those with an initial diagnosis of myocardial infarction.
The results of ENACT highlight the diagnostic challenges posed by patients admitted with a provisional diagnosis of an acute coronary syndrome. Among patients admitted with suspected acute coronary syndrome, almost half had a final diagnosis other than unstable angina: 25% were a relatively low-risk group with non-cardiac conditions, while 20% were potentially high-risk patients in whom the final diagnosis was myocardial infarction. ST elevation was strongly associated with an initial and final diagnosis of myocardial infarction, however the final diagnosis was myocardial infarction in 24% of those with other ECG changes. In the majority of those with normal ECGs (59%), the final diagnosis was unstable angina. However, the fact that 10% had a final diagnosis of myocardial infarction is a matter for concern and reflects the limited diagnostic sensitivity of the ECG [27] . With regard to biochemical markers, admission creatine kinase-MB was reported to be unavailable in 14% and 16% of those admission diagnoses of unstable angina and myocardial infarction respectively. Admission creatine kinase-MB levels were above the upper limit of normal in only 48% of all patients with an initial diagnosis of myocardial infarction and only 59% of those for whom creatine kinase-MB levels were available. However, peak creatine kinase-MB levels were above normal in 76% of all those with a final diagnosis of myocardial infarction and 93% of those for whom peak levels were available. However, it should be noted that no definitions were provided and participants were asked to apply their usual diagnostic criteria. These findings emphasize the need for objective real-time diagnostic tools to enable high-risk patients to be identified as early as possible.
It is important to acknowledge the limitations of the ENACT study. It was not a population-based epidemiological study and some bias may have been introduced with respect to the selection of participating centres; in common with most other registry studies, no on-site monitoring of the data collection was undertaken. In addition, the data from countries providing relatively few patients are not robust.
However, despite these limitations, it provides the first pan-European data on hospital management of acute coronary syndromes based on real-life practice from a mixture of academic, non-academic, public and private institutions. It has generated valuable data on the frequency of unstable angina relative to that of acute myocardial infarction, using myocardial infarction frequency as the reference standard. Moreover, it is reassuring that in general the ENACT findings are consistent with other data, where these are available.
Conclusions
The ENACT study provides pan-European reference data on acute coronary syndromes. It has shown, for the first time, that unstable angina is more common than myocardial infarction as a cause of hospital admission in Europe and that the relative proportions are similar in the 17 countries studied. It has also shown that unstable angina is a major burden on hospital resources and that the average hospital stay is almost as long as for myocardial infarction. ENACT has confirmed the wide variation in the use of angiography and percutaneous coronary intervention across Europe. It also provides, for the first time, a 'snapshot' of current medical treatment of acute coronary syndromes in Europe. The study thus provides a useful benchmark of current practice and a basis for future studies.
The urgent need for information on acute coronary syndromes has already been recognized in the establishment of the GRACE registry (Global Registry of Acute Coronary Events) and by the European Society of Cardiology, which has made the survey of acute coronary syndromes a priority within the Euro Heart Survey [28] programme. In the meantime, pending completion of these studies, ENACT provides valuable reference data on the relative frequency and hospital management of acute coronary syndromes and a baseline reference for future comparative data.
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